Journal Information
Vol. 73. Issue 1.
Pages 134 (January - February 2007)
Share
Share
Download PDF
More article options
Visits
6562
Vol. 73. Issue 1.
Pages 134 (January - February 2007)
Case Report
Open Access
Malignant otitis externa
Visits
6562
Gilberto Gattaz1,
Corresponding author
gilberto@gattaz.com.br

Mailing Address: Dr. Gilberto Gattaz - Rua Moreira Guimarães, 699 Indianópolis São Paulo SP 04073-031. Tel. (0xx11) 5056-0100 ramal 139
, Lucimar Santos Sperotto2, Larissa Matos Rebouças3
1 Associate Professor PUC-SP. Otorhinolaryngologist - Serviço de ORL do Hospital dos Defeitos da Face
2 ENT Resident - Hospital dos Defeitos da Face. Intern
3 ENT Resident - Hospital dos Defeitos da Face. Intern
This item has received

Under a Creative Commons license
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Full Text
INTRODUCTION

Malignant otitis externa (MOE) is a severe, invasive and necrotizing infectious disease that starts in the external auditory meatus (EAM) and may progress to the parotid region, mastoid, middle ear and skull base1.

It affects mainly the diabetic, the elderly and immunosuppressed patients. Main etiological agent: P. aeruginosa.

Symptoms: Otalgia, mal-odorous otorrhea and local edema

Diagnosis is carried out through anamnesis, clinical exam, finding the germ and complementary exams. Temporal bone CT Scans allows for the identification of MOE erosions and the MRI defines its expansion to the skull base. Although non-specific, ESR (erythrocyte sedimentation rate) is a parameter that measures MOE's evolution2,3.

Differential diagnosis: benign neoplasia of the EAM, malignant neoplasia of the EAM and cholesteatoma4.

Treatment: IV ciprofloxacin and continue with it orally until HSS normalization.

CASE PRESENTATION

JB, 53 years old, with intense left side otalgia, irradiating to the temporal region and half of his face.

It's been developing for one month, after swimming in the ocean, treated with ear drops, without improvement. Patient reports never having ear problems or D. mellitus.

Otoscopy: EAM edema, purulent otorrhea and tenderness. Tympanic membrane was not visible. Under the assumption of an external otitis media, we medicated the patient with IM betamethasone, amoxicillin 1.5g/day per os and topical ciprofloxacin.

The patient did not show significant improvement. We then requested a CT scan and prescribed ciprofloxacin per os 1.5g/day and topical drops for maintenance treatment.

CT scan (figure 1) showed a hyperdense lesion occluding all the EAM, erosion of its walls and the petrous bone, with inflammatory mastoiditis. Differential diagnosis did not rule out a neoplastic lesion; however the latter was ruled out by MRI. Glucose levels, CBC and ESR within normal ranges.

Figure 1.

Temporal bone CT Scan - Left Ear.

(0.05MB).

Considering a diagnosis of MOE, we chose to use 750mg of ciprofloxacin BID per os.

After one month without complaints, otoscopy showed a significant improvement.

Tonal audiometry: mixed hearing loss, more intense in the higher frequencies with a 10 to 25dBHL bone-air gap.

Tympanometry in −250 dcPa. No stapedial reflexes.

DISCUSSION

D. Mellitus may represent a predisposing factor for MOE1,2,5,6; however all tests were normal. The germ was not found because of previous treatment. MOE diagnosis was based on the anamnesis and the patient's response to treatment. We have to bear in mind that the patient had not had any prior ear infection. The inefficiency of the previous treatment allowed us to consider the possibility of MOE.

CT scan findings (Figure 1) have corroborated that information. Please notice that Chaussé's spur, epitympanum and the incus-malleus joint are intact. The mastoid disease is a reactional inflammatory process. MRI ruled out malignant neoplasia or cholesteatoma. The disease progression and the image findings indubitably led us to conclude for diagnosis of MOE in a patient lacking conventional predisposing factors.

Oral ciprofloxacin or ceftazidime and IV cefoperazone, associated to ciprofloxacin per os represent the drug treatment of choice. In the present case, we chose to use ciprofloxacin per os for 2 weeks3, with both clinical and otoscopic improvement. Considering the disease's course and the possibility of sequela and fatal complications, we stress the need to be attentive towards this condition, and not underestimate any external otitis, always suspect of MOE, especially in cases of unexpected developments regarding the prescribed treatment.

REFERENCES
[1]
Guatimosim MHE .
Doenças da orelha externa..
Tratado de Otorrinolaringologia., 1a ed., pp. 17-18
[2]
Weinroth SE , et al.
Malignant Otitis Externa in AIDS Patients: Case Report and Review of the Literature..
ENTJ, 7 (1994), pp. 771-778
[3]
Louie TJ .
Ciprofloxacin: an oral quinolone for the tratment of infection with gram-negative pathogens..
Can Med Assoc J, 150 (1994), pp. 669-676
[4]
Ribeiro FAQ , et al.
Otite externa necrosante benigna ou osteíte necrosante benigna do meato acústico externo..
Relato de caso. Rev Bras Otorrinolaringol, 67 (2001), pp. 119-122
[5]
Voegels RL , et al.
Otite externa maligna: experiência de 10 anos..
Rev Bras Otorrinolaringol, 60 (1994), pp. 56-58
[6]
Barrow HN , Levenson MJ .
Necrotizing malignant external otitis caused by Staphylococcus epidermidis..
Arch Otolaryngol Head Neck Surg, 118 (1992), pp. 94-96

Hospital dos Defeitos da Face - Cruz Vermelha Brasileira

Paper submitted to the ABORL-CCF SGP (Management Publications System) on March 30th, 2005 and accepted for publication on May 30th, 2006. cod. 202.

Copyright © 2007. Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial
Idiomas
Brazilian Journal of Otorhinolaryngology (English Edition)
Article options
Tools
en pt
Announcement Nota importante
Articles submitted as of May 1, 2022, which are accepted for publication will be subject to a fee (Article Publishing Charge, APC) payment by the author or research funder to cover the costs associated with publication. By submitting the manuscript to this journal, the authors agree to these terms. All manuscripts must be submitted in English.. Os artigos submetidos a partir de 1º de maio de 2022, que forem aceitos para publicação estarão sujeitos a uma taxa (Article Publishing Charge, APC) a ser paga pelo autor para cobrir os custos associados à publicação. Ao submeterem o manuscrito a esta revista, os autores concordam com esses termos. Todos os manuscritos devem ser submetidos em inglês.